The Daily Bolus: The Triple Agonist Showdown & Surprising GLP-1 Wins in Type 1 Diabetes
Welcome to today’s edition of The Daily Bolus! The incretin landscape is rapidly evolving into the era of the “triple agonist,” with Eli Lilly and […]
Incretins
Beyond Blood Sugar: Could incretins shield against diabetes complications?
Could incretins therapy effectively reduce the effects and thus risk of diabetes complications amongst all those with diabetes? A discussion of the mechanisms and actions that might lead to this conclusion.